Arbutus Presents HBV Data at Upcoming Scientific Conferences
September 22 2017 - 4:54PM
Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading
Hepatitis B Virus (HBV) therapeutic solutions company, today
announced presentation of HBV data at the following scientific
conferences.
Discovery on Target: Targeting HBV, Sept
25, 2017, Boston, MA Presentations Include:
- RNA Interference: A New Tool in the Toolbox for Treatment of
HBV by Amy Lee, Senior Director, Research
- HBV Capsid Assembly Inhibitors by Rene Rijnbrand, Vice
President, Head of Biology
Discovery on Target: Emerging
Oligonucleotide Therapeutics, Sept 27-28, 2017, Boston, MA
Presentation Includes:
- RNAi Based Human Therapy for Chronic Hepatitis B Infection by
Amy Lee, Senior Director, Research
These presentations will be available by
visiting the Investor section of www.arbutusbio.com and selecting
Events and Presentations.
About Arbutus
Arbutus Biopharma Corporation is a
biopharmaceutical company dedicated to discovering, developing and
commercializing a cure for patients suffering from chronic HBV
infection. Arbutus is headquartered in Vancouver, BC, and has
facilities in Warminster, PA. For more information, visit
www.arbutusbio.com.
Contact Information
InvestorsAdam CutlerSenior Vice President,
Corporate AffairsPhone: 604-419-3200 Email:
acutler@arbutusbio.com
Tiffany TolmieManager, Investor RelationsPhone: 604-419-3200
Email: ttolmie@arbutusbio.com
MediaDavid SchullRusso PartnersPhone:
858-717-2310Email: david.schull@russopartnersllc.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2023 to Apr 2024